Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Joint Budget Committee approves March 2025 pharmacy formulary, adds biosimilars for Stelara
Summary
The Joint Budget Committee reviewed and approved March 2025 updates to the pharmacy formulary and related medical drug recommendations, including adding multiple biosimilars to replace the brand-name drug Stelara; changes take effect around June 1.
The Joint Budget Committee reviewed and approved updates to the March 2025 pharmacy formulary and related medical drug recommendations, including the addition of several biosimilars that will replace the brand-name drug Stelara on the state formulary.
Grant Wallace, director of the Employee Benefits Division, told the committee that the formulary changes include “Yaxentik and the next 3. Those are the biosimilars for…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
